Key Takeaways:
Fresenius Medical Care Q2 operating income rose 23% to EUR 569 million, beating consensus, but shares fell on US volume weakness.
"We have wrapped up our US clinic consolidation," Chief Executive Officer Helen Giza said, as the company closed roughly 100 clinics to streamline its network.
Group revenue increased 4% at constant currency to EUR 4,861 million, slightly above the EUR 4,792 million consensus. Net income before special items rose 13% to EUR 303 million ($349 million), ahead of the EUR 288 million estimate. Basic earnings per share of EUR 0.81 beat the EUR 0.68 consensus.
Comparable US treatment volume slipped 0.9% in the quarter, a steeper drop than the prior period, sending American depositary receipts down as much as 3.9% in New York. Management confirmed full-year guidance for broadly flat revenue and operating income growth within a range between positive and negative mid-single digits.
Fresenius Medical Care, the world's largest dialysis provider, operates roughly 4,000 clinics across more than 50 countries. The US business remains the key swing factor, with elevated patient deaths and lower treatment volumes weighing on results since the pandemic disrupted patient volumes.
The dialysis services business drove the profit increase, with favorable reimbursement helping the unit cope with softer US treatment activity. The Care Enablement segment, which makes dialysis equipment and supplies technical services, saw income excluding special items fall 6% and remains under strain in China.
The cost-savings program, targeting EUR 1.2 billion in cumulative savings by the end of next year, delivered EUR 67 million in lasting savings during the quarter. A temporary Medicare payment boost for certain new drugs and equipment, known as TDAPA, has flattered first-half profits, but management expects it to taper off and work against earnings in the second half.
Fresenius is deploying the 5008X dialysis machine, a model established in Europe, now in use at 227 US clinics, to improve treatment trends. The company has also been coping with unusually high death rates among its US dialysis patients since Covid-19, which has dented earnings. The stock had gained about 10% this year before Monday's close.
The unchanged guidance shows management expects the TDAPA tailwind to fade in the second half, while persistent US volume declines remain the core growth challenge. Investors will watch whether the 5008X rollout and further cost savings can reverse the trend in coming quarters.
This article is for informational purposes only and does not constitute investment advice.
